Larimar Therapeutics (LRMR) Return on Capital Employed (2014 - 2025)
Larimar Therapeutics (LRMR) posted Return on Capital Employed of 169.45% for Q4 2025, down 49.78% on a QoQ basis from 113.13% in Q3 2025, and down 12039.0% year-over-year from N/an in Q4 2024.
Larimar Therapeutics (LRMR) Return on Capital Employed (2014 - 2025) Analysis & Trends
Larimar Therapeutics' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 169.45% for Q4 2025.
- Quarterly Return on Capital Employed fell 12039.0% year-over-year to 169.45% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 169.45% (down 12039.0% YoY) and the FY2025 annual result came in at 159.37%, down 8591.0% from the prior year.
- Return on Capital Employed was 169.45% for Q4 2025 at Larimar Therapeutics, down from 113.13% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 29.72% in Q2 2024 and bottomed at 169.45% in Q4 2025.
- A 5-year average of 63.07% and a median of 55.67% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed slumped 959756 bps — and 2022, when it jumped 4747 bps.
- Larimar Therapeutics' Return on Capital Employed stood at 67.78% in 2021, then surged by 55 bps to 30.69% in 2022, then sank by 50 bps to 46.17% in 2023, then retreated by 6 bps to 49.06% in 2024, then sank by 245 bps to 169.45% in 2025.
- Business Quant data shows LRMR's Return on Capital Employed at 169.45% in Q4 2025, 113.13% in Q3 2025, and 81.34% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | -169.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -169.45% |
| Sep 30, 2025 | -113.13% |
| Jun 30, 2025 | -81.34% |
| Mar 31, 2025 | -64.60% |
| Dec 31, 2024 | -49.06% |
| Sep 30, 2024 | -34.82% |
| Jun 30, 2024 | -29.72% |
| Mar 31, 2024 | -31.94% |
| Dec 31, 2023 | -46.17% |
| Sep 30, 2023 | -37.56% |
| Jun 30, 2023 | -33.52% |
| Mar 31, 2023 | -30.77% |
| Dec 31, 2022 | -30.69% |
| Sep 30, 2022 | -39.74% |
| Jun 30, 2022 | -73.15% |
| Mar 31, 2022 | -71.51% |
| Dec 31, 2021 | -67.78% |
| Sep 30, 2021 | -75.24% |
| Jun 30, 2021 | -62.28% |
| Mar 31, 2021 | -118.98% |